The CREST-E study of creatine for Huntington disease: A randomized controlled trial
Hersch SM, Schifitto G, Oakes D, Bredlau AL, Meyers CM, Nahin R, Rosas HD
Published in Neurology
Abstract
Large phase III trial of high-dose creatine for early manifest Huntington disease.
Methodology
Double-blind placebo-controlled multicenter trial of up to 40 g/day creatine for up to 48 months.
Key Findings
The trial stopped early for futility; functional decline was not delayed and gastrointestinal adverse effects were more frequent.
Conclusions
Creatine should not be used to delay functional decline in early manifest Huntington disease.
Limitations
Stopped early for futility before planned enrollment; an exploratory sex subgroup signal was unconfirmed.
Supplements Studied
Our data do not support the use of creatine treatment for delaying functional decline in early manifest HD.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.